Diabetic Gastroparesis Treatment Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Diabetic Gastroparesis Treatment market size was valued at USD 3496.7 million in 2022 and is forecast to a readjusted size of USD 5136.1 million by 2029 with a CAGR of 5.6% during review period.

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes. During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.

Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.

Market is not concentrated. Sumitomo, Johnson & Johnson, Sanofi are the leaders of the industry, and hold the key technologies and patent, with high-end customers. Top 3 manufacturer accounted for 7.4% market share in 2019.

This report is a detailed and comprehensive analysis for global Diabetic Gastroparesis Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Diabetic Gastroparesis Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Diabetic Gastroparesis Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Diabetic Gastroparesis Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Diabetic Gastroparesis Treatment market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Diabetic Gastroparesis Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Diabetic Gastroparesis Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Sumitomo
   Johnson & Johnson
   Sanofi
   Medtronic
   Pfizer
   Teva
   Boston Scientific

   Drugs
   Surgical Treatment Products

   Hospital Pharmacies
   Private Clinics
   Drug Stores
   E-Commerce

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of the Diabetic Gastroparesis Treatment Market in 2025?

The market will likely see increased demand due to the rising prevalence of diabetes and its complications, including gastroparesis. Innovative therapies, such as the use of novel medications and devices, will provide better treatment options for patients. Advances in technology for diagnosis and treatment are expected to improve patient outcomes, thus boosting market growth.

What weaknesses could hinder the growth of this market?

The high cost of new treatments and therapies may limit access for a broader patient population, particularly in emerging markets. The complexity of treating gastroparesis in diabetic patients also creates challenges, as the condition is often difficult to diagnose and manage. Additionally, the lack of sufficient awareness about the disease and its treatment options may hinder market penetration.

What opportunities exist in the Diabetic Gastroparesis Treatment Market?

There is significant opportunity for the development of more effective and affordable treatment options. Research into personalized medicine and better diagnostic tools can open new avenues for growth. Expanding healthcare infrastructure in developing regions presents an opportunity to increase the global reach of treatment options.

What threats could impact the market in 2025?

The market could face regulatory challenges as new treatments undergo approval processes, leading to delays in availability. Competition from alternative treatments, including non-pharmaceutical options, could limit the market share of certain drug therapies. Economic downturns or healthcare budget cuts could also affect market growth in some regions.

How will political factors impact the Diabetic Gastroparesis Treatment Market in 2025?

Government policies regarding healthcare spending and insurance coverage will directly influence access to treatments. Political stability and regulatory frameworks in various countries will determine the ease with which new therapies are approved. Additionally, government initiatives to combat diabetes and its complications may drive market growth.

What economic factors could influence the market?

Economic conditions such as healthcare funding, disposable income, and the cost of treatment will play a significant role in shaping the market. In developed countries, higher healthcare spending will support the adoption of advanced treatments, while in emerging markets, economic constraints could limit access to newer therapies, potentially slowing growth.

How will social factors affect the market?

There is growing awareness of diabetes and its complications, including gastroparesis, which may lead to a greater demand for treatment. Changing lifestyle patterns and an aging population could increase the prevalence of diabetic gastroparesis, expanding the patient base. Public health campaigns and education will also affect how patients manage their condition.

What technological advancements will impact the market?

Technological advancements in diagnostic tools and treatment devices, such as the development of continuous glucose monitoring and wearable gastric stimulators, will revolutionize the way diabetic gastroparesis is treated. Innovations in personalized medicine and drug delivery systems will improve treatment efficacy and patient compliance.

What environmental factors could influence the market?

Environmental factors like pollution and climate change may indirectly affect the prevalence of diabetes and its related complications, potentially increasing the need for treatments. Moreover, the environmental sustainability of manufacturing processes for drugs and devices could come under scrutiny, affecting market dynamics.

What legal factors should be considered?

Changes in healthcare regulations and patent laws can affect the market. Intellectual property protection for innovative treatments will play a key role in encouraging investment in research and development. Additionally, evolving healthcare policies regarding drug pricing and reimbursement will influence how treatments are made accessible to patients.

Who are the suppliers in the Diabetic Gastroparesis Treatment Market in 2025?

Suppliers include pharmaceutical companies, medical device manufacturers, and research institutions involved in developing drugs and devices for diabetic gastroparesis. Key players are those producing treatments like prokinetic agents, antiemetic drugs, gastric electrical stimulators, and diagnostic tools.

What are the inputs required for this market?

Inputs include research and development investments, raw materials for drug manufacturing, technological innovations for diagnostic devices, and skilled labor for production. Regulatory approvals and clinical trial data are also crucial for the market’s advancement.

What processes are involved in the Diabetic Gastroparesis Treatment Market?

Processes include the development of drugs and medical devices, clinical trials, regulatory approval, marketing, distribution, and patient care. Ongoing research to improve treatment efficacy and patient outcomes is also a key process, along with physician and patient education for effective treatment.

Who are the customers in the Diabetic Gastroparesis Treatment Market?

Customers are primarily healthcare providers, including hospitals, clinics, and physicians, who prescribe treatments. End consumers are diabetic gastroparesis patients who require treatment, as well as caregivers and family members involved in managing the condition.

What are the outputs of the Diabetic Gastroparesis Treatment Market?

Outputs include effective treatments, including medications and medical devices, for managing diabetic gastroparesis. Additionally, the market produces advancements in patient care, clinical research findings, and improved treatment protocols aimed at reducing complications related to gastroparesis.

How strong is the threat of new entrants in the Diabetic Gastroparesis Treatment Market in 2025?

The threat of new entrants is moderate. While the market has growth potential due to rising diabetes-related complications, the high costs of research and development, regulatory hurdles, and the need for significant clinical evidence make it challenging for new players to enter successfully.

How strong is the bargaining power of suppliers in this market?

The bargaining power of suppliers is moderate to high. Suppliers of active pharmaceutical ingredients, medical devices, and diagnostic tools have considerable influence, especially when they offer proprietary technologies or critical materials. However, competition among suppliers and technological advancements may reduce their power over time.

How strong is the bargaining power of buyers in the Diabetic Gastroparesis Treatment Market?

The bargaining power of buyers is moderate. Healthcare providers and patients generally have limited negotiating power due to the specialized nature of diabetic gastroparesis treatments. However, with increasing awareness and treatment options, patients and healthcare systems might exert more influence on pricing and treatment choices in the future.

What is the threat of substitute products in this market?

The threat of substitutes is low to moderate. While lifestyle changes, dietary adjustments, and alternative therapies like acupuncture may provide some relief, they do not offer the same level of efficacy as pharmaceutical treatments or medical devices specifically designed for diabetic gastroparesis, making substitutes less viable for long-term management.

How intense is the competitive rivalry in the Diabetic Gastroparesis Treatment Market?

The competitive rivalry is moderate to high. The market has a mix of established pharmaceutical companies, medical device manufacturers, and emerging players developing specialized treatments. While the market is growing, competition for market share and the need for continuous innovation drive the rivalry among key players.

What are the key raw materials required for the Diabetic Gastroparesis Treatment Market in 2025?

Key raw materials include active pharmaceutical ingredients (APIs) for drugs, such as prokinetic agents and antiemetic drugs, as well as components for medical devices like gastric electrical stimulators. Additionally, raw materials for manufacturing diagnostic equipment and consumables, like sensors, are essential for the market.

What role do suppliers play in the Diabetic Gastroparesis Treatment Market?

Suppliers play a crucial role in providing the necessary chemicals, technologies, and components needed to develop treatments and medical devices. They also supply the machinery and tools required for production and quality testing, ensuring that the treatments meet regulatory standards and patient safety requirements.

How is research and development influencing the upstream factors of the market?

Research and development (R&D) are driving innovation in drug therapies and medical devices. Significant investments in R&D are required to develop more effective treatments for diabetic gastroparesis, which influences upstream activities like raw material sourcing, technological development, and collaboration with research institutions to discover new solutions.

What regulatory factors impact the upstream processes?

Regulatory factors, such as approval from health authorities (e.g., the FDA, EMA), heavily influence upstream processes. Manufacturers must comply with strict regulations in drug development, clinical trials, and device manufacturing. These regulations impact the availability of raw materials, timelines for production, and the cost of compliance.

How do external market conditions affect upstream activities?

External factors like economic conditions, global supply chain stability, and geopolitical risks can influence the availability and cost of raw materials. For instance, fluctuations in the prices of raw materials or disruptions in global trade can increase production costs or delay timelines for the introduction of new treatments and devices to the market.

What are the key processes involved in the midstream of the Diabetic Gastroparesis Treatment Market?

The key processes include the manufacturing, packaging, and distribution of medications and medical devices used to treat diabetic gastroparesis. This stage also involves clinical testing, regulatory approval, and ensuring compliance with safety standards before products reach healthcare providers and patients.

How do manufacturers contribute to the midstream activities?

Manufacturers are responsible for scaling production of treatment drugs and medical devices. They also handle the quality control and packaging of products to ensure that they meet regulatory standards. Collaboration with research teams and logistics partners is crucial to ensure timely availability and delivery to the market.

What is the role of distribution channels in this market?

Distribution channels, such as wholesalers, healthcare providers, and pharmacies, play a critical role in delivering treatments to the end-user. Efficient logistics networks ensure that drugs and medical devices reach hospitals, clinics, and patients in a timely manner, which is crucial for maintaining patient care continuity.

How does the market address quality control and regulatory compliance during the midstream phase?

Regulatory bodies, such as the FDA and EMA, ensure that treatments and devices undergo rigorous quality control and testing. Manufacturers must follow good manufacturing practices (GMP) and ensure that all products meet the required safety standards before reaching the market. This phase also includes ongoing monitoring of product performance post-launch.

How does competition affect the midstream processes?

Competitive pressure drives manufacturers to innovate, reduce production costs, and enhance efficiency in distribution. Companies may invest in new technologies to streamline production processes or improve supply chain management, enabling faster and more cost-effective delivery of products to market.

What are the key activities in the downstream phase of the Diabetic Gastroparesis Treatment Market?

The downstream phase involves the final stages of delivery, including patient access, physician prescription, and treatment administration. It also includes post-treatment monitoring, patient education, and follow-up care to ensure effective management of diabetic gastroparesis.

How do healthcare providers contribute to the downstream process?

Healthcare providers play a critical role in diagnosing diabetic gastroparesis, prescribing appropriate treatments, and managing patient care. They educate patients on treatment options, potential side effects, and lifestyle adjustments, ensuring that treatments are tailored to individual needs for better outcomes.

What is the role of patient access programs in this market?

Patient access programs are designed to help patients obtain medications and treatments, especially in cases where cost or insurance coverage may be a barrier. These programs can include discounts, financial assistance, and information on available treatment options, improving patient adherence and outcomes.

How does the market ensure patient adherence to treatments?

To ensure adherence, pharmaceutical companies and healthcare providers offer educational resources, personalized care plans, and support services. Some companies may provide patient support hotlines or mobile apps to track treatment progress, while healthcare providers offer counseling and follow-up appointments to monitor effectiveness.

How does competition impact the downstream phase?

Increased competition leads to greater innovation in patient engagement and adherence programs. Companies may offer better pricing models, improved patient support services, or value-added benefits like extended warranties on medical devices, aiming to capture patient loyalty and improve treatment outcomes.

Chapter 1, to describe Diabetic Gastroparesis Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Diabetic Gastroparesis Treatment, with revenue, gross margin and global market share of Diabetic Gastroparesis Treatment from 2018 to 2023.
Chapter 3, the Diabetic Gastroparesis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Diabetic Gastroparesis Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Diabetic Gastroparesis Treatment.
Chapter 13, to describe Diabetic Gastroparesis Treatment research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Diabetic Gastroparesis Treatment
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Diabetic Gastroparesis Treatment by Type
       1.3.1 Overview: Global Diabetic Gastroparesis Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Diabetic Gastroparesis Treatment Consumption Value Market Share by Type in 2022
       1.3.3 Drugs
       1.3.4 Surgical Treatment Products
   1.4 Global Diabetic Gastroparesis Treatment Market by Application
       1.4.1 Overview: Global Diabetic Gastroparesis Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Hospital Pharmacies
       1.4.3 Private Clinics
       1.4.4 Drug Stores
       1.4.5 E-Commerce
   1.5 Global Diabetic Gastroparesis Treatment Market Size & Forecast
   1.6 Global Diabetic Gastroparesis Treatment Market Size and Forecast by Region
       1.6.1 Global Diabetic Gastroparesis Treatment Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Diabetic Gastroparesis Treatment Market Size by Region, (2018-2029)
       1.6.3 North America Diabetic Gastroparesis Treatment Market Size and Prospect (2018-2029)
       1.6.4 Europe Diabetic Gastroparesis Treatment Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Diabetic Gastroparesis Treatment Market Size and Prospect (2018-2029)
       1.6.6 South America Diabetic Gastroparesis Treatment Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Diabetic Gastroparesis Treatment Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Sumitomo
       2.1.1 Sumitomo Details
       2.1.2 Sumitomo Major Business
       2.1.3 Sumitomo Diabetic Gastroparesis Treatment Product and Solutions
       2.1.4 Sumitomo Diabetic Gastroparesis Treatment Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Sumitomo Recent Developments and Future Plans
   2.2 Johnson & Johnson
       2.2.1 Johnson & Johnson Details
       2.2.2 Johnson & Johnson Major Business
       2.2.3 Johnson & Johnson Diabetic Gastroparesis Treatment Product and Solutions
       2.2.4 Johnson & Johnson Diabetic Gastroparesis Treatment Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Johnson & Johnson Recent Developments and Future Plans
   2.3 Sanofi
       2.3.1 Sanofi Details
       2.3.2 Sanofi Major Business
       2.3.3 Sanofi Diabetic Gastroparesis Treatment Product and Solutions
       2.3.4 Sanofi Diabetic Gastroparesis Treatment Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Sanofi Recent Developments and Future Plans
   2.4 Medtronic
       2.4.1 Medtronic Details
       2.4.2 Medtronic Major Business
       2.4.3 Medtronic Diabetic Gastroparesis Treatment Product and Solutions
       2.4.4 Medtronic Diabetic Gastroparesis Treatment Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Medtronic Recent Developments and Future Plans
   2.5 Pfizer
       2.5.1 Pfizer Details
       2.5.2 Pfizer Major Business
       2.5.3 Pfizer Diabetic Gastroparesis Treatment Product and Solutions
       2.5.4 Pfizer Diabetic Gastroparesis Treatment Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Pfizer Recent Developments and Future Plans
   2.6 Teva
       2.6.1 Teva Details
       2.6.2 Teva Major Business
       2.6.3 Teva Diabetic Gastroparesis Treatment Product and Solutions
       2.6.4 Teva Diabetic Gastroparesis Treatment Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Teva Recent Developments and Future Plans
   2.7 Boston Scientific
       2.7.1 Boston Scientific Details
       2.7.2 Boston Scientific Major Business
       2.7.3 Boston Scientific Diabetic Gastroparesis Treatment Product and Solutions
       2.7.4 Boston Scientific Diabetic Gastroparesis Treatment Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Boston Scientific Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Diabetic Gastroparesis Treatment Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Diabetic Gastroparesis Treatment by Company Revenue
       3.2.2 Top 3 Diabetic Gastroparesis Treatment Players Market Share in 2022
       3.2.3 Top 6 Diabetic Gastroparesis Treatment Players Market Share in 2022
   3.3 Diabetic Gastroparesis Treatment Market: Overall Company Footprint Analysis
       3.3.1 Diabetic Gastroparesis Treatment Market: Region Footprint
       3.3.2 Diabetic Gastroparesis Treatment Market: Company Product Type Footprint
       3.3.3 Diabetic Gastroparesis Treatment Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Diabetic Gastroparesis Treatment Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Diabetic Gastroparesis Treatment Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Diabetic Gastroparesis Treatment Consumption Value Market Share by Application (2018-2023)
   5.2 Global Diabetic Gastroparesis Treatment Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2029)
   6.2 North America Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2029)
   6.3 North America Diabetic Gastroparesis Treatment Market Size by Country
       6.3.1 North America Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2029)
       6.3.2 United States Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       6.3.3 Canada Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       6.3.4 Mexico Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2029)
   7.2 Europe Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2029)
   7.3 Europe Diabetic Gastroparesis Treatment Market Size by Country
       7.3.1 Europe Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2029)
       7.3.2 Germany Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       7.3.3 France Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       7.3.5 Russia Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       7.3.6 Italy Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Diabetic Gastroparesis Treatment Market Size by Region
       8.3.1 Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Region (2018-2029)
       8.3.2 China Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       8.3.3 Japan Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       8.3.4 South Korea Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       8.3.5 India Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       8.3.7 Australia Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2029)
   9.2 South America Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2029)
   9.3 South America Diabetic Gastroparesis Treatment Market Size by Country
       9.3.1 South America Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2029)
       9.3.2 Brazil Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       9.3.3 Argentina Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Diabetic Gastroparesis Treatment Market Size by Country
       10.3.1 Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2029)
       10.3.2 Turkey Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)
       10.3.4 UAE Diabetic Gastroparesis Treatment Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Diabetic Gastroparesis Treatment Market Drivers
   11.2 Diabetic Gastroparesis Treatment Market Restraints
   11.3 Diabetic Gastroparesis Treatment Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry
   11.5 Influence of COVID-19 and Russia-Ukraine War
       11.5.1 Influence of COVID-19
       11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

   12.1 Diabetic Gastroparesis Treatment Industry Chain
   12.2 Diabetic Gastroparesis Treatment Upstream Analysis
   12.3 Diabetic Gastroparesis Treatment Midstream Analysis
   12.4 Diabetic Gastroparesis Treatment Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Diabetic Gastroparesis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Diabetic Gastroparesis Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Diabetic Gastroparesis Treatment Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Diabetic Gastroparesis Treatment Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Sumitomo Company Information, Head Office, and Major Competitors
   Table 6. Sumitomo Major Business
   Table 7. Sumitomo Diabetic Gastroparesis Treatment Product and Solutions
   Table 8. Sumitomo Diabetic Gastroparesis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Sumitomo Recent Developments and Future Plans
   Table 10. Johnson & Johnson Company Information, Head Office, and Major Competitors
   Table 11. Johnson & Johnson Major Business
   Table 12. Johnson & Johnson Diabetic Gastroparesis Treatment Product and Solutions
   Table 13. Johnson & Johnson Diabetic Gastroparesis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Johnson & Johnson Recent Developments and Future Plans
   Table 15. Sanofi Company Information, Head Office, and Major Competitors
   Table 16. Sanofi Major Business
   Table 17. Sanofi Diabetic Gastroparesis Treatment Product and Solutions
   Table 18. Sanofi Diabetic Gastroparesis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Sanofi Recent Developments and Future Plans
   Table 20. Medtronic Company Information, Head Office, and Major Competitors
   Table 21. Medtronic Major Business
   Table 22. Medtronic Diabetic Gastroparesis Treatment Product and Solutions
   Table 23. Medtronic Diabetic Gastroparesis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Medtronic Recent Developments and Future Plans
   Table 25. Pfizer Company Information, Head Office, and Major Competitors
   Table 26. Pfizer Major Business
   Table 27. Pfizer Diabetic Gastroparesis Treatment Product and Solutions
   Table 28. Pfizer Diabetic Gastroparesis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Pfizer Recent Developments and Future Plans
   Table 30. Teva Company Information, Head Office, and Major Competitors
   Table 31. Teva Major Business
   Table 32. Teva Diabetic Gastroparesis Treatment Product and Solutions
   Table 33. Teva Diabetic Gastroparesis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Teva Recent Developments and Future Plans
   Table 35. Boston Scientific Company Information, Head Office, and Major Competitors
   Table 36. Boston Scientific Major Business
   Table 37. Boston Scientific Diabetic Gastroparesis Treatment Product and Solutions
   Table 38. Boston Scientific Diabetic Gastroparesis Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. Boston Scientific Recent Developments and Future Plans
   Table 40. Global Diabetic Gastroparesis Treatment Revenue (USD Million) by Players (2018-2023)
   Table 41. Global Diabetic Gastroparesis Treatment Revenue Share by Players (2018-2023)
   Table 42. Breakdown of Diabetic Gastroparesis Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 43. Market Position of Players in Diabetic Gastroparesis Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 44. Head Office of Key Diabetic Gastroparesis Treatment Players
   Table 45. Diabetic Gastroparesis Treatment Market: Company Product Type Footprint
   Table 46. Diabetic Gastroparesis Treatment Market: Company Product Application Footprint
   Table 47. Diabetic Gastroparesis Treatment New Market Entrants and Barriers to Market Entry
   Table 48. Diabetic Gastroparesis Treatment Mergers, Acquisition, Agreements, and Collaborations
   Table 49. Global Diabetic Gastroparesis Treatment Consumption Value (USD Million) by Type (2018-2023)
   Table 50. Global Diabetic Gastroparesis Treatment Consumption Value Share by Type (2018-2023)
   Table 51. Global Diabetic Gastroparesis Treatment Consumption Value Forecast by Type (2024-2029)
   Table 52. Global Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2023)
   Table 53. Global Diabetic Gastroparesis Treatment Consumption Value Forecast by Application (2024-2029)
   Table 54. North America Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2023) & (USD Million)
   Table 55. North America Diabetic Gastroparesis Treatment Consumption Value by Type (2024-2029) & (USD Million)
   Table 56. North America Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2023) & (USD Million)
   Table 57. North America Diabetic Gastroparesis Treatment Consumption Value by Application (2024-2029) & (USD Million)
   Table 58. North America Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2023) & (USD Million)
   Table 59. North America Diabetic Gastroparesis Treatment Consumption Value by Country (2024-2029) & (USD Million)
   Table 60. Europe Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2023) & (USD Million)
   Table 61. Europe Diabetic Gastroparesis Treatment Consumption Value by Type (2024-2029) & (USD Million)
   Table 62. Europe Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2023) & (USD Million)
   Table 63. Europe Diabetic Gastroparesis Treatment Consumption Value by Application (2024-2029) & (USD Million)
   Table 64. Europe Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2023) & (USD Million)
   Table 65. Europe Diabetic Gastroparesis Treatment Consumption Value by Country (2024-2029) & (USD Million)
   Table 66. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2023) & (USD Million)
   Table 67. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Type (2024-2029) & (USD Million)
   Table 68. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2023) & (USD Million)
   Table 69. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Application (2024-2029) & (USD Million)
   Table 70. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Region (2018-2023) & (USD Million)
   Table 71. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value by Region (2024-2029) & (USD Million)
   Table 72. South America Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2023) & (USD Million)
   Table 73. South America Diabetic Gastroparesis Treatment Consumption Value by Type (2024-2029) & (USD Million)
   Table 74. South America Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2023) & (USD Million)
   Table 75. South America Diabetic Gastroparesis Treatment Consumption Value by Application (2024-2029) & (USD Million)
   Table 76. South America Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2023) & (USD Million)
   Table 77. South America Diabetic Gastroparesis Treatment Consumption Value by Country (2024-2029) & (USD Million)
   Table 78. Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Type (2018-2023) & (USD Million)
   Table 79. Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Type (2024-2029) & (USD Million)
   Table 80. Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Application (2018-2023) & (USD Million)
   Table 81. Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Application (2024-2029) & (USD Million)
   Table 82. Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Country (2018-2023) & (USD Million)
   Table 83. Middle East & Africa Diabetic Gastroparesis Treatment Consumption Value by Country (2024-2029) & (USD Million)
   Table 84. Diabetic Gastroparesis Treatment Raw Material
   Table 85. Key Suppliers of Diabetic Gastroparesis Treatment Raw Materials

List of Figures

   Figure 1. Diabetic Gastroparesis Treatment Picture
   Figure 2. Global Diabetic Gastroparesis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Diabetic Gastroparesis Treatment Consumption Value Market Share by Type in 2022
   Figure 4. Drugs
   Figure 5. Surgical Treatment Products
   Figure 6. Global Diabetic Gastroparesis Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 7. Diabetic Gastroparesis Treatment Consumption Value Market Share by Application in 2022
   Figure 8. Hospital Pharmacies Picture
   Figure 9. Private Clinics Picture
   Figure 10. Drug Stores Picture
   Figure 11. E-Commerce Picture
   Figure 12. Global Diabetic Gastroparesis Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 13. Global Diabetic Gastroparesis Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 14. Global Market Diabetic Gastroparesis Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 15. Global Diabetic Gastroparesis Treatment Consumption Value Market Share by Region (2018-2029)
   Figure 16. Global Diabetic Gastroparesis Treatment Consumption Value Market Share by Region in 2022
   Figure 17. North America Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 18. Europe Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 19. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 20. South America Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 21. Middle East and Africa Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 22. Global Diabetic Gastroparesis Treatment Revenue Share by Players in 2022
   Figure 23. Diabetic Gastroparesis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 24. Global Top 3 Players Diabetic Gastroparesis Treatment Market Share in 2022
   Figure 25. Global Top 6 Players Diabetic Gastroparesis Treatment Market Share in 2022
   Figure 26. Global Diabetic Gastroparesis Treatment Consumption Value Share by Type (2018-2023)
   Figure 27. Global Diabetic Gastroparesis Treatment Market Share Forecast by Type (2024-2029)
   Figure 28. Global Diabetic Gastroparesis Treatment Consumption Value Share by Application (2018-2023)
   Figure 29. Global Diabetic Gastroparesis Treatment Market Share Forecast by Application (2024-2029)
   Figure 30. North America Diabetic Gastroparesis Treatment Consumption Value Market Share by Type (2018-2029)
   Figure 31. North America Diabetic Gastroparesis Treatment Consumption Value Market Share by Application (2018-2029)
   Figure 32. North America Diabetic Gastroparesis Treatment Consumption Value Market Share by Country (2018-2029)
   Figure 33. United States Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 34. Canada Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 35. Mexico Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 36. Europe Diabetic Gastroparesis Treatment Consumption Value Market Share by Type (2018-2029)
   Figure 37. Europe Diabetic Gastroparesis Treatment Consumption Value Market Share by Application (2018-2029)
   Figure 38. Europe Diabetic Gastroparesis Treatment Consumption Value Market Share by Country (2018-2029)
   Figure 39. Germany Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 40. France Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 41. United Kingdom Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 42. Russia Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 43. Italy Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 44. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value Market Share by Type (2018-2029)
   Figure 45. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value Market Share by Application (2018-2029)
   Figure 46. Asia-Pacific Diabetic Gastroparesis Treatment Consumption Value Market Share by Region (2018-2029)
   Figure 47. China Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 48. Japan Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 49. South Korea Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 50. India Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 51. Southeast Asia Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 52. Australia Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 53. South America Diabetic Gastroparesis Treatment Consumption Value Market Share by Type (2018-2029)
   Figure 54. South America Diabetic Gastroparesis Treatment Consumption Value Market Share by Application (2018-2029)
   Figure 55. South America Diabetic Gastroparesis Treatment Consumption Value Market Share by Country (2018-2029)
   Figure 56. Brazil Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 57. Argentina Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 58. Middle East and Africa Diabetic Gastroparesis Treatment Consumption Value Market Share by Type (2018-2029)
   Figure 59. Middle East and Africa Diabetic Gastroparesis Treatment Consumption Value Market Share by Application (2018-2029)
   Figure 60. Middle East and Africa Diabetic Gastroparesis Treatment Consumption Value Market Share by Country (2018-2029)
   Figure 61. Turkey Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 62. Saudi Arabia Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 63. UAE Diabetic Gastroparesis Treatment Consumption Value (2018-2029) & (USD Million)
   Figure 64. Diabetic Gastroparesis Treatment Market Drivers
   Figure 65. Diabetic Gastroparesis Treatment Market Restraints
   Figure 66. Diabetic Gastroparesis Treatment Market Trends
   Figure 67. Porters Five Forces Analysis
   Figure 68. Manufacturing Cost Structure Analysis of Diabetic Gastroparesis Treatment in 2022
   Figure 69. Manufacturing Process Analysis of Diabetic Gastroparesis Treatment
   Figure 70. Diabetic Gastroparesis Treatment Industrial Chain
   Figure 71. Methodology
   Figure 72. Research Process and Data Source